AC
CYTK icon

Armistice Capital’s Cytokinetics CYTK Stock Holding History

Armistice Capital’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$50.4M Sell
764,538
-228,228
-23% -$14.5M 0.9% 17
2025
Q4 		$63.1M Sell
992,766
-204,102
-17% -$12.7M 0.75% 20
2025
Q3 		$65.8M Sell
1,196,868
-115,481
-9% -$4.76M 0.98% 13
2025
Q2 		$43.4M Buy
1,312,349
+288,959
+28% +$10.1M 0.75% 18
2025
Q1 		$41.1M Sell
1,023,390
-288,610
-22% -$13.3M 0.62% 35
2024
Q4 		$61.7M Sell
1,312,000
-584,575
-31% -$30.4M 0.84% 23
2024
Q3 		$100M Sell
1,896,575
-169,416
-8% -$9.44M 1.6% 9
2024
Q2 		$112M Buy
2,065,991
+540,303
+35% +$32.6M 1.41% 6
2024
Q1 		$107M Buy
+1,525,688
New +$118M 1.42% 7

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Armistice Capital's CYTK Position: Q1 2026 in Review

Armistice Capital reduced its Cytokinetics (CYTK) stake by 23% in Q1 2026, selling an estimated $14.5M and leaving 764,538 shares worth $50.4M. The position accounts for 0.9% of the portfolio, ranked #17.

Armistice Capital first reported a position in CYTK in Q1 2024 and has held it in 9 quarters since. The position peaked at $112M in Q2 2024. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Armistice Capital held 764,538 shares of Cytokinetics worth $50.4M as of Q1 2026.
  • Armistice Capital sold 228,228 Cytokinetics shares in Q1 2026, an estimated $14.5M.
  • Cytokinetics made up 0.9% of Armistice Capital's portfolio in Q1 2026, its #17 holding.
  • Armistice Capital first reported a position in Cytokinetics in Q1 2024 and has held it in 9 quarters since.
  • Armistice Capital's Cytokinetics position peaked at $112M in Q2 2024.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Armistice Capital's 13F filing for Q1 2026, filed 15 May 2026.